August 17, 2026
Antibiotic treatment can disrupt the gut microbiome and lead to dysbiosis. Discover its consequences and the importance of strain-specific probiotic selection.
The human gut is home to a highly diverse microbial ecosystem composed of bacteria, archaea, fungi, viruses and other microorganisms. Together, these microbial communities interact with each other and with their host, contributing to functions such as digestion, production of microbial metabolites, maintenance of the intestinal barrier and modulation of immune responses.
Rather than describing the presence of one particular microorganism, dysbiosis refers to an alteration in the composition or function of the microbial ecosystem compared with a balanced state. It may involve a loss of microbial diversity, depletion of beneficial or commensal microorganisms, expansion of potentially harmful microorganisms, or changes in microbial metabolic activity.
Many factors can influence the gut microbiota, including diet, age, environment, disease and medication. Antibiotics are among the best documented disruptors.
Antibiotics have transformed modern medicine. By targeting bacteria responsible for infections, they save millions of lives and remain essential tools in clinical practice. However, their action is not limited to pathogenic bacteria.
Studies in humans have shown that exposure to antibiotics can rapidly lead to gut dysbiosis by reducing the abundance of commensal and beneficial bacterial populations. The degree of disruption varies considerably according to the antibiotic used, treatment duration and dose, as well as the individual's initial microbiome.
When the intestinal ecosystem is disrupted, several consequences may occur.
Antibiotic exposure can reduce the richness and diversity of the intestinal microbial community. Because microbial diversity contributes to ecosystem stability and resilience, its reduction may affect the microbiota's ability to perform its usual functions.
A balanced intestinal microbiota contributes to colonization resistance: the collective ability of resident microorganisms to limit the establishment or excessive growth of potentially pathogenic organisms through competition for nutrients and space, metabolite production and interactions with the host.
When antibiotics disturb this ecosystem, colonization resistance may decrease, creating ecological opportunities for opportunistic microorganisms.
One clinically important example is Clostridioides difficile (formerly Clostridium difficile). Antibiotic exposure is a major risk factor for C. difficile infection because disruption of the resident gut microbiota can reduce the natural barriers that normally limit its proliferation.
Diarrhea is one of the best-known adverse effects associated with antibiotic therapy. Antibiotic-associated diarrhea (AAD) can result from several mechanisms, including changes in microbial composition and metabolism. In a proportion of cases, it is associated with C. difficile infection.
The gut microbiota participates in numerous metabolic and immune-related processes. A major disruption of microbial communities can therefore modify microbial metabolite production and microbiota-host interactions. The precise effects depend on the nature and duration of the disturbance and remain an active area of research.
After treatment stops, the microbiota often moves back toward its initial composition, but recovery is not necessarily immediate or complete. Research has shown substantial inter-individual variability, with some bacterial taxa taking longer to recover and, in some cases, remaining altered for extended periods.
Understanding how antibiotics affect the gut microbiome, and how selected probiotics may help in specific situations, is an important area of research for scientists, healthcare professionals and probiotic developers.
Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Their potential role around antibiotic treatment has been extensively studied, particularly for the prevention of antibiotic-associated diarrhea.
However, one principle is essential: not all probiotics are equivalent.
Benefits demonstrated for a particular microorganism or strain, at a defined dose and for a specific indication, cannot automatically be extrapolated to another probiotic. Strain identity, formulation, dose, stability and clinical evidence all matter.
This strain-specific approach is reflected in clinical recommendations. For instance, in its position paper on pediatric gastrointestinal disorders, the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) states that, when probiotics are considered for the prevention of antibiotic-associated diarrhea in children with relevant risk factors, healthcare professionals may recommend high doses (at least 5 billion CFU/day) of Lacticaseibacillus rhamnosus GG, started simultaneously with antibiotic treatment.
This does not mean that every probiotic can prevent antibiotic-associated diarrhea, nor that probiotics should be used indiscriminately. It illustrates why probiotic selection must be connected to the intended benefit and supported by appropriate evidence.
For probiotic developers, understanding the biological mechanisms behind a desired effect is a key part of selecting and developing the right strain.
Depending on the microorganism, investigated mechanisms may include competition with other microorganisms, production of antimicrobial compounds or metabolites, interactions with the intestinal barrier, and modulation of host immune responses. These properties are strain-dependent and need to be characterized with appropriate in vitro, preclinical and, where required, clinical approaches.
The challenge is therefore not simply to add “a probiotic” to a formulation. It is to identify a well-characterized strain, manufacture it consistently, preserve its viability and functional properties throughout production and shelf life, and connect the final formulation to the scientific evidence relevant to its intended use.
The relationship between antibiotics, dysbiosis and the gut microbiome highlights a broader reality of probiotic development: microbial science and manufacturing performance must work together.
At Bioprox Healthcare, we combine decades of fermentation expertise with probiotic and postbiotic manufacturing capabilities to support partners throughout product development. From strain production and process development to scale-up and finished-product manufacturing, our CDMO approach is designed to transform scientifically relevant microbial solutions into robust, reproducible products.
Because when it comes to the microbiome, choosing the right microorganism is only the beginning. Producing it reliably with the right quality and the required performance is what turns science into a viable product.
This article is intended for scientific and professional information and does not constitute medical advice. Probiotic use should be evaluated according to the microorganism/strain, intended population, formulation, dose and applicable clinical evidence and regulations.
Interested by our services?
S.svg){kind=logo}